Get the Stockscreener App
3.195
5.79%
0.175
After Hours:
3.19
-0.005
-0.16%
Mannkind Corp stock is traded at $3.195, with a volume of 3.25M.
It is up +5.79% in the last 24 hours and down -10.25% over the past month.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
See More
Previous Close:
$3.02
Open:
$3.02
24h Volume:
3.25M
Relative Volume:
0.62
Market Cap:
$1.03B
Revenue:
$360.78M
Net Income/Loss:
$-23.91M
P/E Ratio:
-40.91
EPS:
-0.0781
Net Cash Flow:
$13.07M
1W Performance:
-6.58%
1M Performance:
-10.25%
6M Performance:
+15.34%
1Y Performance:
-38.91%
1-Day Range:
$2.995
$3.20
1-Week Range:
$2.895
$3.405
52-Week Range:
$2.23
$6.51
Mannkind Corp Stock (MNKD) Company Profile
Name
Mannkind Corp
Sector
Industry
Phone
818-661-5000
Address
1 CASPER STREET, DANBURY, CA
Compare MNKD vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNKD
Mannkind Corp
|
3.195 | 1.03B | 360.78M | -23.91M | 13.07M | -0.0781 |
VRTX
Vertex Pharmaceuticals Inc
|
508.74 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.35 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.50 | 53.23B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.30 | 42.34B | 5.76B | 514.49M | 1.10B | 4.4813 |
Mannkind Corp Stock (MNKD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-27-26 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-13-25 | Initiated | Leerink Partners | Outperform |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Oct-10-25 | Initiated | Leerink Partners | Outperform |
| Jul-16-25 | Resumed | H.C. Wainwright | Buy |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Feb-10-25 | Initiated | Wedbush | Outperform |
| Dec-20-24 | Initiated | Wells Fargo | Overweight |
| Dec-19-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-10-23 | Initiated | Wedbush | Outperform |
| May-14-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-24-19 | Initiated | Oppenheimer | Outperform |
| Oct-25-19 | Initiated | Cantor Fitzgerald | Overweight |
| May-14-19 | Initiated | BTIG Research | Buy |
| Mar-04-19 | Initiated | SVB Leerink | Outperform |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Feb-28-18 | Downgrade | Maxim Group | Hold → Sell |
| Nov-01-17 | Downgrade | Maxim Group | Buy → Hold |
| Oct-10-17 | Initiated | H.C. Wainwright | Buy |
| Oct-06-17 | Reiterated | Maxim Group | Buy |
| Aug-11-17 | Initiated | Maxim Group | Buy |
| May-10-16 | Reiterated | Piper Jaffray | Underweight |
| May-10-16 | Reiterated | RBC Capital Mkts | Underperform |
| Jan-06-16 | Reiterated | Piper Jaffray | Underweight |
| Jan-06-16 | Reiterated | RBC Capital Mkts | Underperform |
| Nov-04-15 | Downgrade | RBC Capital Mkts | Outperform → Underperform |
| Sep-09-15 | Downgrade | Piper Jaffray | Neutral → Underweight |
| Aug-03-15 | Reiterated | RBC Capital Mkts | Outperform |
| May-11-15 | Downgrade | JP Morgan | Neutral → Underweight |
| May-11-15 | Reiterated | MLV & Co | Hold |
| Apr-16-15 | Reiterated | RBC Capital Mkts | Outperform |
View All
Mannkind Corp Stock (MNKD) Latest News
MannKind to Participate in the Chardan Healthcare Conference - GlobeNewswire Inc.
A heart-failure injector delivers a full dose in under 10 seconds. Urine output was similar to treatment into a vein. - Stock Titan
New data supports Furoscix ReadyFlow autoinject... - Pluang
MannKind Presents New Data Showing Furoscix ReadyFlow Delivers IV-Equivalent Diuresis Across Injection Sites at HFSA 2026 - Quiver Quantitative
MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD) - GlobeNewswire Inc.
MNKD Maintains Buy Rating -- Price Target Lowered to $5.00 by Truist Securities - GuruFocus
MannKind stock weighs 43 percent revenue growth against losses - AD HOC NEWS
Delaware Court Ruling Boosts MannKind (MNKD) Outlook Amid Liquid - GuruFocus
MNKD Stock Draws Trader Focus On Rose Pharma GLP-1 Deal - StocksToTrade
MNKD Stock In Focus After Rose Pharma GLP-1 Licensing Deal - timothysykes.com
MNKD Stock In Focus After Rose Pharma GLP-1 Licensing Deal - timothysykes.com
Steven Binder sells $128,477 of MannKind (MNKD) stock By Investing.com - Investing.com South Africa
Director Steven Binder Sells 39,051 Shares of MannKind Corp (MNK - GuruFocus
Steven Binder sells $128,477 of MannKind (MNKD) stock By Investing.com - Investing.com Nigeria
Form 4 MannKind Corp For: 28 September By Investing.com - Investing.com Nigeria
Steven Binder sells $128,477 of MannKind (MNKD) stock - Investing.com
Steven Binder sells $128,477 of MannKind (MNKD) stock By Investing.com - Investing.com Canada
Form 144 MannKind Corporation For: 25 September - Investing.com India
Form 144 MannKind Corporation For: 25 September By Investing.com - Investing.com Canada
Shares valued at $128,478 are proposed for sale by MannKind (MNKD) director Steven Binder. - Stock Titan
Danbury Company Reports Positive Results In Lung Disease Drug Trial - Patch
MannKind Corporation (MNKD) Options ChainYahoo Finance - Yahoo! Finance Canada
MannKind Corporation (MNKD) Stock Analysis: Exploring a 127.68% Potential Upside in the Biotech Space - DirectorsTalk Interviews
MNKD Stock Rises 8% On Furoscix ReadyFlow Approval And $50M Funding Boost - Stocktwits
Mannkind Stock Price Forecast. Should You Buy MNKD? - StockInvest.us
MannKind Sees Early ReadyFlow Demand as Pediatric Afrezza Launch Gains Momentum - TradingView
MannKind (MNKD) Bets On Inhaled Weight Loss Amid Widening Losses - Yahoo Finance
Cantor Fitzgerald reiterates Overweight on MannKind stock at $8 By Investing.com - Investing.com Nigeria
Cantor Fitzgerald reiterates Overweight rating on MannKind stock By Investing.com - Investing.com Nigeria
Cantor Fitzgerald reiterates Overweight on MannKind stock at $8 By Investing.com - Investing.com South Africa
Cantor Fitzgerald reiterates Overweight rating on MannKind stock By Investing.com - Investing.com Canada
Cantor Fitzgerald reiterates Overweight on MannKind stock at $8 By Investing.com - Investing.com India
Cantor Fitzgerald reiterates Overweight rating on MannKind stock - investing.com
MNKD Reiterates by Cantor Fitzgerald -- Price Target Maintained at $6.50 - GuruFocus
MannKind (NASDAQ: MNKD) director lines up more stock sales under trading plan - stocktitan.net
CT drugmaker partners on development of inhaled weight-loss treatment - Hartford Business Journal
MannKind inks obesity deal with Rose Pharma - thepharmaletter.com
Breathing In GLP-1: MannKind Partners With Rose Pharma for Inhaled Weight Management Molecule - Benzinga
MannKind signs global GLP-1 inhalation collaboration deal - grafa.com
MannKind Expands Into Weight Loss With Rose Pharma Deal – Here’s What Investors Are Watching - Yahoo Finance
MNKD Looks 44.2% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
MNKD Looks 44.2% Undervalued on GF Value™ Amid Speculative Growt - GuruFocus
MannKind partners with Rose Pharma on inhaled GLP-1 therapy By Investing.com - Investing.com India
MannKind partners with Rose Pharma on inhaled GLP-1 therapy - investing.com
MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management - The Manila Times
MannKind and Rose Pharma Enter Worldwide Collaboration to Develop Inhaled ROSE-010 Technosphere for Weight Management - Quiver Quantitative
MannKind and Rose Pharma Inc Enter Licensing and - GlobeNewswire
MannKind and Rose Pharma Inc Enter Licensing and - GlobeNewswire
A rapid-acting, short-duration inhaled treatment is being developed for weight management - stocktitan.net
MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management - Yahoo Finance
Mannkind Corp Stock (MNKD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Mannkind Corp Stock (MNKD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| STEVEN BINDER | Director |
Sep 25 '26 |
Proposed Sale |
3.29 |
39,051 |
128,478 |
0 |
| STEVEN BINDER | Director |
Sep 10 '26 |
Proposed Sale |
3.94 |
33,558 |
132,219 |
0 |
| Binder Steven B. | Director |
Sep 10 '26 |
Sale |
3.81 |
33,558 |
127,856 |
752,309 |
| STEVEN BINDER | Director |
Aug 07 '26 |
Proposed Sale |
3.89 |
39,051 |
151,908 |
0 |
| Binder Steven B. | Director |
Aug 07 '26 |
Sale |
4.06 |
39,051 |
158,547 |
785,867 |
| Binder Steven B. | Director |
Jul 17 '26 |
Sale |
4.06 |
52,485 |
213,089 |
824,918 |
| DAVID THOMSON | Officer |
Jul 17 '26 |
Proposed Sale |
4.04 |
24,109 |
97,400 |
0 |
| STEVEN BINDER | Director |
Jul 17 '26 |
Proposed Sale |
4.04 |
52,485 |
212,039 |
0 |
| Thomson David | EVP Genl Counsel & Secretary |
Jul 17 '26 |
Sale |
4.05 |
24,109 |
97,641 |
797,554 |
| Tross Stuart A | Chief People & Workpl Officer |
Jul 15 '26 |
Option Exercise |
0.00 |
93,790 |
0 |
1,123,950 |
8.24%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):